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Abstract 
We have studied the expression and regulation of the interleukin-6 receptor (gp80) and its signal transducer gp130 in primary human blood 
monocytes. Here, we show that freshly isolated human monocytes express mRNAs for gp80 and gp130. In contrast o a previous report [(1989) FEBS 
L&t. 249, 27-301 we find that neither lipopolysaccharide nor interleukin-6 (IL-6) lead to a down-regulation of IL-6 receptor mRNA in monocytes. 
Also in the human monocytic cell line Mono Mac 6 no effect of IL-6 on receptor mRNA levels was observed. For signal transducer gp130 mRNA 
in monocytes a small and transient up-regulation by IL-6 was found. 
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1. Introduction 
Interleukin-6 (IL-6) is a multifunctional cytokine 
which is synthesized by many different cells after appro- 
priate stimulation. It acts on a wide spectrum of target 
cells and exerts multiple functions during the immune 
response, hematopoiesis, neural differentiation and the 
acute phase reaction [l-5]. IL-6 acts via a cell surface 
receptor complex composed of two subunits: an 80 kDa 
IL-6 binding protein (IL-6 receptor) and a 130 kDa sig- 
nal transducing protein, gp130 [6-81. The regulation of 
the expression of the IL-6 receptor and of gp130 was 
studied in a number of different cells [9-191. In human 
hepatoma cells HepG2 and Hep3B, in rat hepatocytes 
and in human epithelial cells UAC it was found that the 
synthetic glucocorticoid dexamethasone but not IL-6 
stimulates the expression of the IL-6-R [9,10,16], 
whereas the expression of gp130 was up-regalated by 
IL-6 and a combination of IL-6 and dexamethasone 
[14,15]. For human monocytes, it was previously re- 
ported that lipopolysaccharide leads to a down-regula- 
tion of IL-6-R mRNA expression and that this down- 
regulation is mediated by interleukin-6 [20,21]. In the 
present study we have analyzed the expression and regu- 
lation of the IL-6-R (gp80) and its signal transducer 
(gpl30) in freshly isolated human monocytes. In contrast 
to the report of Bauer et al. [20,21] we find that neither 
LPS nor IL-6 do significantly alter the expression of the 
IL-6-R whereas for gp130 a weak stimulatory effect of 
IL-6 was found. 
*Corresponding author. Fax: (49) (241) 888 8428. 
Abbreviations: IL-6, interleukin-6; ILd-R, interleukin-6-receptor; LPS, 
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2. Materials and methods 
2. I. Chemicals 
TFG-/I1 (1 x lo6 U/mg) was purchased from Genxyme (Cambridge, 
MA). Human recombinant interleukind (5 x lo6 B-cell stimulatory fac- 
tor-2 units/mg protein) was kindly provided by Drs. T. Hirano and T. 
Hishimoto (Osaka University, Japan). The biological activity of the 
IL-6 used was checked with the B9 assay (see section 2.4). Fetal calf 
serum (FCS) and RPM1 were from Gibco (Eggenstein, Germany). 
Restriction enzymes and random primed DNA labeling kit were ob- 
tained from Boehringer (Mannheim, Germany). 
2.2. Isolation of human monocytes 
Human monocytes were isolated from buffy coats (Institut fur Trans- 
fusionsmedixin, RWTH Aachen, Germany) with a Ficoll-Paque gra- 
dient followed by hypotonic density ccntrifugation in Percoll[22]. The 
cells were cultivated in Teflon bags in RPM1 1640 medium plus 5% 
heat-inactivated autologous erum at a cell density of 2 x lO’?ml in 7.5% 
CO* humiditied atmosphere. All media and sera used were checked for 
low endotoxin concentration (C 0.05 &ml) by using the Limulus 
amelocyte lysate assay (Sigma, Mtlnchen, Germany). Morphological 
differentiation of cells was studied by staining with Mayer-Hglmalaun 
(Merck, Darmstadt, Germany). Purity of monocytes was greater than 
85% in all experiments. 
2.3. MonoMac 6 cell line 
The monoblastic leukemia cell line Mono Mac 6 was kindly provided 
by Dr. H.W.L. Ziegler-Heitbrock (Institut fti Immunology, Miinchen, 
Germany). The cells were cultured in RPM1 1640 medium containing 
2 x non-essential amino acids, 9 &ml insulin, 1 mM oxalacetate, 1 
mM sodium pyruvate and 10% FCS. 
2.4. IL-&assay 
The IL-6 assay was performed using the murine plasmacytoma cell 
line B9 kindly provided by Dr. L. Aarden (Amsterdam, The Nether- 
lands) [23]. Cells were cultured with dilutions of supematants from 
human monocytes for 68 h on microculture plates (5 x lo3 cells/well). 
The cell number was determined using the Celltiter 96 proliferation 
assay (Promega, Madison, IL) as described by the manufacturer. The 
absorbance at 550 nm was recorded using an ELISA reader. One B9 
unit is the amount of IL-6 that resulted in hall-maximal growth of the 
B9 cells. Approximately 120 B9 units correspond to 1 B-cell stimulatory 
factor-2 (BSF-2) unit. 
2.5. RNA isolation 
RNA from monocytes was isolated using the method of Chirgwin et 
al. [24]. Human monocytes were dissolved in 2 ml of 4 M guanidinium 
tbiocyanate containing 25 mM sodium citrate, pH 7, 0.5% sodium 
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N-laurylsarcosine, 0.1 M 2-mercaptoethanol and 0.1% Antifoam A 
(Sigma). The solution was sheared by passage through a needle (26- 
G x 23 mm) 5-6 times and centrifugation through a 5.7 M cesium 
chloride cushion for 20 h at 36,000 rpm and 20°C in a Beckman 
ultracentrifuge. The RNA pellet was dissolved in water (containing 
0.07% diethyl pyrocarbonate) and precipitated for 30 min at -80°C 
after adding two volumes of 96% ethanol. This precipitation was re- 
peated once. The pellet was washed twice with 70% ethanol, dried and 
dissolved in water. The amount of RNA was quantified by absorbance 
measurements at 260 mn. 
2.6. Northern blot analysti 
5 ,ug of total RNA were separated on 1% denaturing agarose gels and 
transfered to GeneScreen Plus membranes @upont-New England Nu- 
clear, Dreieich, Germany). The filters were prehybridiid at 68°C for 
2 h in 10% dextran sulfate, 1 M sodium chloride, 1% SDS, and hybrid- 
ized in the same solution with cDNA fragments labeled by random 
priming [25]. Hybridisations were performed with the a 1.2 kb PM/ 
XhoI IL-6-R-cDNA, a 1.1 kb EcoRI IL&cDNA, a 3.0 kb AccII/ 
BarnHI gpl3O-cDNA and a 1.3 kb PstI GAPDH-cDNA fragment, 
respectively. 
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Fig. 1. (A) Messenger-RNA levels for IL-6, gp80 and gp130 in human 
monocytes treated with LPS. Human monocytes were incubated with 
100 ng/ml LPS for 2 and 18 h. RNA was isolated and 5 pug were 
subjected to Northern blot analysis. GAPDH was used as a control for 
equal loading of the gels. (B) IL-6 secretion by LPS-stimulated mon- 
ocytes as measured in the Bg-cell proliferation assay. 
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Fig. 2. Messenger-RNA levels for gp80 (A) and gp130 (B) in human 
monocytes upon IL-6 stimulation. Human monccytes were incubated 
with IL-6 (100 BSF-2 units/ml) for the times indicated in the figure. 
RNA was isolated and 5 gg were subjected to Northern blot analysis. 
Two different experiments are documented. 
3. Results 
Human blood monocytes were prepared from butfy 
coats using Ficoll-Paque and Percoll gradients. Cultiva- 
tion was performed in Teflon bags with 5% autologous 
serum which prevented the adherence of monocytes to 
a substratum known to activate these cells [26,27]. Mon- 
ocytes were incubated with LPS, a well-known inducer 
of cytokine synthesis in these cells [28-301. Two and 18 h 
after stimulation, cells were harvested and subjected to 
a Northern blot analysis. A strong induction of IL-6 
mRNA expression was detected 2 h after LPS addition 
(Fig. lA, upper panel). This induction was accompanied 
by an increase in bioactive IL-6 protein in the medium 
(Fig. 1B). When the expression of the IL-6-R (gp80) and 
gp130 was analyzed in these cells, mRNAs for both pro- 
teins were detected. However, no regulation by LPS was 
observed (Fig. 1, middle panels). 
When human monocytes were stimulated with IL-6 
for 18 h, again no significant change in IL-6-R (gp80) 
mRNA levels were seen (Fig. 2A). This result was repro- 
duced in several independent experiments with mon- 
ocytes from more than ten different donors. An increase 
of expression of gp80 between 0 and 18 h of incubation 
was regularly observed in non-stimulated cells and is 
probably due to the ‘stress’ on the cells during the puri- 
fication procedure (Fig. 2A). 
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receptor protein might take place in these cells upon IL-6 
incubation. 
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Fig. 3. GpSO mRNA expression in Mono Mac 6 cells treated with IL-6, 
dexamethasone and TGF-DI. Mono Mac 6 cells were stimulated for 
18 h with IL-6 (100 BSF-2 units/ml) and/or dexamethasone (10q7 M), 
and TGF-Bl (5 ng/ml). RNA was isolated and detected by Northern 
blot analysis. 
When expression of gpl30 mRNA was studied, a tran- 
sient increase was seen 4 h after stimulation with IL-6 
(Fig. 2B). However, at 21 hours basal levels were reached 
again. Dexamethasone had no effect on the expression 
of IL-6-R and gp130 mRNAs (data not shown). 
When mRNA levels for the IL-6-R were analyzed in 
the monoblastic leukemia cells Mono Mac 6, which dis- 
play many functional and phenotypic characteristics of 
mature monocytes [31], again no regulation by IL-6 and/ 
or dexamethasone was found. Also TGF-Bl had no ef- 
fect (Fig. 3). 
4. Discussion 
From our data we conclude that IL-6 does not impair 
the mRNA expression of its receptor (gp80) in primary 
human blood monocytes. This fmding contradicts a pre- 
vious report, which described the down-regulation of 
IL-6-R mRNA by LPS and IL-6 [20,21]. This discrep- 
ancy might be due to the different procedures used for 
the isolation and culture of monocytes. Bauer and co- 
workers used an additional adherence step to further 
increase the purity of their monocyte preparation and 
they cultured their cells on plastic dishes [21]. However, 
it is known that adherence of monocytes to a substratum 
leads to their activation [26,27]. Therefore, it is possible 
that the IL-6 effect observed by these authors is due to 
a co-activation of the cells by adherence. 
For signal transducer gp130 a small and transient up- 
regulation by IL-6 was found. A similar regulation of 
gp130 by IL-6 was observed in other cell types [14,15]. 
In striking contrast to the inability of IL-6 to impair 
the IL-6-R mRNA expression is its ability to down-regu- 
late IL-6-R surface protein. We have recently demon- 
strated that after binding of IL-6 to its surface receptor 
in HepG2 cells, ligand and receptor are endocytosed 
thereby leading to a loss of IL-6 surface binding sites 
[32]. This process is mediated by the signal transducer 
gp130 (Dittrich et al., submitted). Although this endocy- 
tosis has not been analyzed in monocytes yet, it is reason- 
able to assume that a similar down-regulation of surface 
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